Psychopharmacology
June 20, 2026
E. C. H. M. Haijen-Bongers, Petra P M Hurks, J. Schepers et al.
RATIONALE: Attention-deficit hyperactivity disorder (ADHD) shows substantial heterogeneity in symptoms and cognitive deficits. According to the Triple Pathway Model, this variability may stem from impairments in three neuropsychological domains: inhibition, motivation, and temporal processing. Repeated low-dose administration of psychedelics is being explored as a treatment for ADHD, but...
Current Opinion in Psychology
August 6, 2025
Iva Totomanova, Eline Haijen, Petra P M Hurks et al.
5 citations
Microdosing psychedelics, the regular use of low doses of LSD or psilocybin, have attracted growing public and scientific interest. This review synthesizes findings from 57 human studies on psychological and physiological outcomes in clinical and non-clinical populations. Reported benefits include improved mood, enhanced cognition, social functioning, and mental health, although findings are...
JAMA Psychiatry
June 1, 2025
Lorenz Mueller, Joyce Santos de Jesus, Yasmin Schmid et al.
14 citations
Microdosing psychedelics, including lysergic acid diethylamide (LSD), has gained attention for its potential benefits in several psychiatric disorders, including attention-deficit/hyperactivity disorder (ADHD). However, LSD's efficacy in reducing ADHD symptoms remains unknown. To determine the safety and efficacy of repeated low doses of LSD in reducing ADHD symptoms compared with placebo. This...
International review of neurobiology
2025
Iva Totomanova, Eline Haijen, Petra P M Hurks et al.
Clinical trials using full doses of psychedelics have provided preliminary evidence supporting their safety and efficacy in treating a variety of physical and psychological conditions. Anecdotal reports indicate that even very small amounts of these substances may provide therapeutic benefits, though robust clinical studies are still needed. This chapter reviews the current experimental studies...
European Psychiatry
2024
Eline Haijen, Petra P M Hurks, Kim P. C. Kuypers
10 citations
Abstract Adults with attention-deficit hyperactivity disorder (ADHD) often struggle with emotion regulation (ER), impacting their empathic skills and relationships. ADHD medication might not be as effective for ER issues as for ADHD symptoms. Microdosing (MD) psychedelics has shown promise for ADHD treatment and previous studies reported social-emotional benefits. Two online prospective studies...
Frontiers in Psychiatry
October 16, 2023
Eline Haijen, Petra P M Hurks, Kim P. C. Kuypers
6 citations
Background Microdosing (MD), repeatedly taking psychedelics in small, non-hallucinogenic amounts, has been practiced by individuals to relieve attention deficit hyperactivity disorder (ADHD) symptoms. Generally, adults diagnosed with ADHD have lower levels of mindfulness and differ in personality structure from non-ADHD adults. How MD affects mindfulness and personality in adults with ADHD...
Neurosci Appl
October 26, 2022
Eline Haijen, Petra P M Hurks, Kim P. C. Kuypers
17 citations
ADHD in adulthood is often overlooked, which negatively affects the individual's well-being. First-line pharmacological interventions are effective in many ADHD patients, relieving symptoms rapidly. However, there seems to be a proportion of individuals who discontinue, or fail to respond to these treatments. For these individuals, alternative treatment options should be explored. A...